Vosoritide for Children with Achondroplasia: Growth Velocity and Pubertal Milestones

Melita Irving

Guy's and St. Thomas' NHS Foundation Trust, Evelina Children's Hospital
London, UK

ACMG
American College of Medical Genetics and Genomics
Translating Genes Into Health®

Financial Disclosure

Text of disclosure here and if they have none then it needs to say “Nothing to disclose”

Vosoritide: Targeted therapy for Achondroplasia

- Achondroplasia (ACH) is the most common form of disproportionate short stature (approx. 1:25,000 live births)[1,2]

- ACH is caused by a pathogenic variant in *FGFR3* that constitutively activates the downstream inhibitory signaling pathway in chondrocytes, leading to impaired endochondral bone growth and multiple complications[1,2]

- CNP down-regulates aberrant FGFR3 signaling in chondrocytes by inhibiting the MAPK-ERK pathway[3,4]

- Vosoritide is based on naturally-occurring CNP engineered to resist degradation and increase the half-life[5]



1. Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet 2007; 370(9582):162-72.
2. Hoover-Fong J et al. Lifetime impact of achondroplasia: Current evidence and perspectives on the natural history. Bone 2021; 146:115872.
3. Yasoda A et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. *Nat Med 2004*; 10(1):80-86.
4. Kreji P et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix proliferation. *J Cell Sci. 2005, 118(Pt 21):5089-100*
5. Lorget F et al. Evaluation of the Therapeutic Potential of a CNP Analog in a Fgfr3 Mouse Model Recapitulating Achondroplasia. *Am J Hum Genet 2012*; 91(6):1108-1114.

Studies in ACH with vosoritide: BMN-111 202/205 and 301/302





BMN 111-202/205 Key Eligibility Criteria

- Age 5 to 14 years old at screening
- ACH, documented by clinical grounds and confirmed by genetic testing

BMN 111-301/302 Key Eligibility Criteria

- Age 5 to <18 years old at screening
- ACH, documented by clinical grounds and confirmed by genetic testing
- Stratified capped enrollment ≤ 20% Tanner I

At least a 6-month period of pre-treatment growth measurements in BMN 111-901, a clinical assessment study to establish baseline growth in children with ACH.

Increase in growth was demonstrated with vosoritide in clinical trials in ACH

- An open-label, 52-week phase 2 trial (BMN 111-202) and its extension study (BMN 111-205) in children with ACH showed that vosoritide treatment resulted in sustained increases in annualized growth velocity (AGV)[1]

- A phase 3 randomized placebo-controlled trial (BMN 111-301) in children with ACH showed a statistically significant improvement in AGV with vosoritide after 52 weeks compared to placebo[2]; AGV improvement sustained after 2 years of vosoritide treatment in extension study (BMN 111-302)[3]

- Vosoritide is approved for use in children with ACH aged ≥5 years in the US and ≥2 years in the EU until closure of epiphyses

1. Savarirayan R et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. *N Engl J Med 2019*;381:25-35.
2. Savarirayan R et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. *Lancet 2020*; 396:684-692.
3. Savarirayan R et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. *Genet Med 2021*; 2**3,** 2443–2447.

ACMG

Analyses Methods

- Data for all subjects in studies 111-202/205 and 111-301/302 whilst receiving 15µg/kg or 30µg/kg doses were considered (n=149)
- Tanner staging was determined by trained physicians
- Mean standing heights, derived from duplicate or triplicate measures taken at each 6-month visit, were used to assess growth and calculate AGV when the subjects progress to the next Tanner stage

Tanner Stage - Age

- Age at which subjects transitioned to next Tanner stage was defined as the mid-time point between two consecutive visits where Tanner stage progressed

Tanner Stage - AGV

- AGV is derived over a 6 month interval
- AGV for Tanner stages II-V is growth velocity at the time the Tanner stage is first recorded
- AGV for Tanner stage I is derived over the last recorded 6 months for this Tanner stage

Demographics of enrolled population — by study (at the first day of vosoritide)

	202 C1 (N=6)	202 C2 (N=6)	202 C3 (n=10)	202 C4 (N=8)	301/302 (N=119)
Age at Day 1 of treatment (y)					
Mean (SD)	8.07 (1.43)	8.49 (2.37)	8.54 (1.54)	7.50 (8.16)	9.18 (2.60)
Min, Max	6.9, 10.9	6.0, 10.8	6.3, 11.1	5.8, 8.7	5.1, 15.9
Age subgroups (%)					
≥ 5 to < 8 years	4 (66.7)	3 (50.0)	4 (40.0)	4 (50.0)	46 (38.7)
≥ 8 to < 11 years	2 (33.3)	3 (50.0)	5 (50.0)	4 (50.0)	37 (31.1)
≥ 11 to < 15 years	0	0	1 (10.0)	0	35 (29.4)
≥ 15 to < 18 years	0	0	0	0	1 (0.8)
Sex (%)					
Male	2 (33.3%)	4 (66.7%)	4(40.0)	3 (37.5)	63 (52.9)
Female	101 (66.7%)	2 (33.3%)	6(60.0)	5 (62.5)	56 (47.1)

Duration on treatment at the time of analyses

Duration	202/205 C1 15 µg/kg	202/205 C2 15 µg/kg	202/205 C3 15 µg/kg	202/205 C4 30 µg/kg	301/302 15 µg/kg
N	6	6	10	8	119
Mean (SD), months	57.33 (16.79)	67.97 (8.12)	70.90 (14.86)	66.69 (2.18)	30.00 (7.22)
Median	59.32	69.54	79.31	66.05	28.75
Min, Max	33.6, 75.0	54.9, 74.8	33.7, 80.4	63.7, 70.9	20.0, 54.6

Tanner Stage by age in children treated with vosoritide in studies 202/205 and 301/302



Whiskers indicate min and max

Age at entry of Tanner Stage of pubertal development in reference to average stature Non-Hispanic White population in USA (NHANES data)

	Average Stature White Females	Females with ACH treated with VOS	Average Stature White Males	Males with ACH treated with VOS
Age at Tanner Stage II*, mean (SE)	11.05 (0.18)	10.45 (1.27)	11.08 (0.18)	12.25 (1.34)
Age at Tanner Stage III*, mean (SE)	12.80 (0.19)	12.36 (1.13)	12.55 (0.29)	13.50 (0.98)
Age at Tanner Stage IV* mean (SE)	15.16 (0.32)	13.06 (1.42)	15.29 (0.19)	14.79 (0.88)
Age at Tanner Stage V*, mean (SE)	16.25 (0.18)	13.65 (0.95)**	16.64 (0.15)	15.27 (1.39)**

*Breast development in Girls; Genitalia development in Boys

**small sample at Tanner V F=4; M=9

Sun SS et al, National estimates of the timing of sexual maturation and racial differences among US children. *Pediatrics. 2002*;110(5):911-9.

AGV over 6 month intervals by Tanner Stage in children treated with vosoritide in studies 202/205 and 301/302



- Mean peak growth velocity on vosoritide was 5.81 and 6.36 cm/year for females and males, respectively
- Mean peak growth velocity occurred at Tanner II for females and Tanner IV for males

Whiskers indicate 2.5th and 97.5th percentiles

Of note, the peak growth velocity in the general US population is 6.65 and 7.66 cm/year for females and males, respectively (Kelley A et al. Age-based reference ranges for annual height velocity in US children. *J Clin Endocrinol Metab. 2014*;99(6):2104-12.)

Individual plots of height for males on vosoritide treatment who reached Tanner IV



Hoover_Fong JE et al. Growth in achondroplasia including stature, weight, weight-for-height and head circumference from CLARITY: achondroplasia natural history study-a multi-center retrospective cohort study of achondroplasia in the US. *Orphanet J Rare Dis. 2021*;16(1):522.

Average stature growth data derived from Centers for Disease Control and Prevention (CDC) reference values:National Center for Health Statistics, https://www.cdc.gov/growthcharts/index.htm.

Individual plots of height for females on vosoritide treatment who reached Tanner IV



Hoover_Fong JE et al. Growth in achondroplasia including stature, weight, weight-for-height and head circumference from CLARITY: achondroplasia natural history study-a multi-center retrospective cohort study of achondroplasia in the US. *Orphanet J Rare Dis. 2021*;16(1):522.

Average stature growth data derived from Centers for Disease Control and Prevention (CDC) reference values:National Center for Health Statistics, https://www.cdc.gov/growthcharts/index.htm

ACMG

Conclusions

- More data are required to determine if the timing of pubertal development in children with ACH treated with vosoritide follows that of average stature children, as well as to understand how the timing compares to that of untreated children with ACH

- Data suggest presence of a growth spurt at Tanner stage II for females and Tanner stage IV for males, but small numbers do not allow a definitive conclusion

- Monitoring of these subjects will continue until subjects reach their adult height in order to help us better understand the potential impact of vosoritide on pubertal development and final height

Acknowledgements

- Study participants
- Investigators and study teams
- Study sponsor: BioMarin Pharmaceutical Inc.
- Co-authors:
  - Julie Hoover-Fong (Johns Hopkins University School of Medicine, Baltimore, MD, USA)
  - Carlos A Bacino (Baylor College of Medicine, Houston, TX, USA)
  - Joel Charrow (Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA)
  - Valerie Cormier-Daire (Institut Imagine, Université Paris Descartes, Hôpital Necker - Enfants Malades, Paris, France)
  - Lynda Polgreen (Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA)
  - Paul Harmatz (UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA)
  - Patricia Dickson (Washington University School of Medicine, St. Louis, MO. USA)
  - Michael B Bober (Nemours Children's Hospital, Wilmington, DE, USA)
  - Klaus Mohnike (Otto-von-Guericke-Universität, Magdeburg, Germany)
  - William R Wilcox (Emory University, Atlanta, GA, USA)
  - John Phillips (Vanderbilt University Medical Center, Nashville, TN, USA)